Description
Abl Protein Active
| Catalog number: | B2013665 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 g |
| Molecular Weight or Concentration: | 121 kDa |
| Supplied as: | Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Abl Protein |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure N Engl J Med. 2019 Dec 12;381(24):2315-2326.
- Chekmarev J, Azad MG, Richardson DR. The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity Cells. 2021 Sep 10;10(9):2382.
- Rachubik P, Piwkowska A. The role of vasodilator-stimulated phosphoprotein in podocyte functioning Cell Biol Int. 2019 Oct;43(10):1092-1101.
- Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors J Immunother Cancer. 2022 Oct;10(10):e005471.
- Fares M, Oerther S, Hultenby K, Gubrianska D, Zhao Y, Abedi-Valugerdi M, Hassan M. COL-3-Induced Molecular and Ultrastructural Alterations in K562 Cells J Pers Med. 2022 Jan 4;12(1):42.
- Kantarjian HM, Giles F, Quints-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia Clin Cancer Res. 2007 Feb 15;13(4):1089-97.
- Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development Cancer Lett. 2006 Mar 8;234(1):73-80.
- Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial Trials. 2020 Oct 28;21(1):897.
- Liu Q, Liang YM, Zheng J, Li XY, Hao MW, Liu L, Chen RA. [Activating effects of protein transduction domain mediated BCR/ABL protein on CML T cells] Zhonghua Xue Ye Xue Za Zhi. 2003 Dec;24(12):644-7.
